Association of matrix metalloproteinase-3 serum level and the promoter 5A/6A polymorphism of the MMP-3 gene with atherosclerotic cerebral infarction

Chinese Journal of Medical Genetics

Volumn 25, Issue 6, 2008, Pages 653-656

  Huang, Xiao Ya ^a   Zhu, Min ^a   Jin, Xiao Ping ^a   Zhang, Dan Hong ^a   Wang, Lin Zhi ^a   Ye, Zu Sen ^b  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerotic cerebral infarction; Genetic polymorphism; Matrix metalloproteinase 3

Indexed keywords

STROMELYSIN;

ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PROMOTER REGION; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CEREBRAL INFARCTION; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 57849094025     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev, 2005, 85:1-31.
2. Beaudeux JL, Giral P, Bruckert E, et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med, 2004, 42:121-131.
3. Beyzade S, Zhang S, Wong Y, et al. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol, 2003, 41:2130-2137.
4. Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progerssion of coronary atherosclerosis. Br Heart J, 1995, 73:209-215.
5. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol, 2003, 42:1429-1437.
6. Zhou X, Huang J, Chen J, et al. Haplotype analysis of the matrix metalloproteinase-3 gene and myocardial infarction in a Chinese Han population. The Beijing Aterosclerosis Study. Thromb Haemost, 2004, 92:867-873.
7. Dunleavy L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis, 2000, 151:587-589.
8. Morgan L, Humphries SE. The genetics of stroke. Curr Opin Lipidol, 2005, 16:193-199.
9. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia, 2005, 50:329-339.
10. Zoppo GJ, Milner R, Mabuchi T, et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke, 2007, 38:646-651.
11. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in mutiplesclerosis; comparison of stages in lesion evolution. J Neuropathol Expurol, 1996, 55:1194-1204.
12. Rosenberg GA, Navratil M, Barone F, et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab, 1996, 16:360-366.
13. Grundström S, Anderson P, Scheipers P, et al. Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4 + T cells. J Biol Chem, 2004, 279:8460-8468.
14. Flex A, Gaetani E, Papaleo P, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke, 2004, 35:2270-2275.